Research programme: neuregulins - Acorda Therapeutics

Drug Profile

Research programme: neuregulins - Acorda Therapeutics

Alternative Names: Neuregulin 2 protein; NRG-2

Latest Information Update: 30 Aug 2012

Price : $50

At a glance

  • Originator Harvard University
  • Developer Acorda Therapeutics
  • Class Nerve tissue proteins; Neuregulins
  • Mechanism of Action Epidermal growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Heart failure; Neurological disorders

Most Recent Events

  • 28 Feb 2012 Acorda Therapeutics' neuregulins research programme is still in preclinical development in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top